Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $43.20

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $43.20.

Separately, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday, September 17th.

Akero Therapeutics Stock Up 7.8 %

NASDAQ:AKRO traded up $2.54 during mid-day trading on Wednesday, reaching $35.28. The stock had a trading volume of 839,844 shares, compared to its average volume of 871,983. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.89 and a quick ratio of 24.89. The stock has a market cap of $2.45 billion, a P/E ratio of -10.35 and a beta of -0.26. The business's 50 day moving average is $28.72 and its 200 day moving average is $25.04. Akero Therapeutics has a fifty-two week low of $13.39 and a fifty-two week high of $37.00.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, sell-side analysts predict that Akero Therapeutics will post -3.64 earnings per share for the current year.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 5,200 shares of Akero Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $27.51, for a total value of $143,052.00. Following the transaction, the insider now directly owns 75,931 shares of the company's stock, valued at $2,088,861.81. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Andrew Cheng sold 1,738 shares of Akero Therapeutics stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares of the company's stock, valued at $15,849,817.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Catriona Yale sold 5,200 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $27.51, for a total value of $143,052.00. Following the transaction, the insider now owns 75,931 shares in the company, valued at $2,088,861.81. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 428,397 shares of company stock worth $12,997,971 in the last 90 days. 7.94% of the stock is owned by company insiders.

Institutional Trading of Akero Therapeutics

Several institutional investors have recently modified their holdings of AKRO. Russell Investments Group Ltd. boosted its position in shares of Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock valued at $31,000 after acquiring an additional 1,183 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock valued at $71,000 after purchasing an additional 446 shares in the last quarter. Eastern Bank bought a new stake in shares of Akero Therapeutics in the 3rd quarter valued at approximately $100,000. Headlands Technologies LLC grew its stake in shares of Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company's stock valued at $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Akero Therapeutics by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company's stock worth $156,000 after buying an additional 1,030 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.